Valneva: schedule confirmed for Covid vaccine

(CercleFinance.com) - Valneva last night confirmed the schedule for clinical trials and regulatory filings for its proposed inactivated Covid-19 vaccine.


The company says that it remains committed to making the product candidate, currently known as VLA2001, available to the market as quickly as possible.

Valneva says it has begun submitting applications for initial marketing authorisation to the European Medicines Agency, the UK MHRA and the Bahrain NHRA.

Based on positive results from Phase 3 studies, the company says regulatory approvals are still expected in the first quarter of 20221.

These statements come as Valneva's stock has lost nearly 27% since the beginning of the year, with investors believing that Omicron's highly contagious nature could result in herd immunity over vaccination.

The share price was still down 2.3% this morning in Paris.

For the record, the European Commission has signed an agreement to supply up to 60 million doses of LAV2001 over a two-year period, with more than 24 million doses expected in 2022.

The vaccine's delivery is currently scheduled to begin in April 2022, subject to regulatory approval from Brussels.


Copyright (c) 2022 CercleFinance.com. All rights reserved.